Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neuroendocrine Tumors 14Carcinoid Tumor 5Gastro-enteropancreatic neuroendocrine tumor 4Acromegaly 4Serotonin Syndrome 2Pituitary Neoplasms 2Neoplasm Metastasis 2Carcinoma, Hepatocellular 2Prostatic Neoplasms 1Pheochromocytoma 1Peritoneal Neoplasms 1Paraganglioma 1Pancreatic Neoplasms 1Neuroendocrine Tumour With Carcinoid Symptoms 1Neuroendocrine Tumors in Lung 1Neoplastic Cells, Circulating 1Neoplasms 1Intestinal Obstruction 1Growth Hormone-Secreting Pituitary Adenoma 1Gigantism 1Gastrointestinal Neoplasms 1Flushing 1Endocrine Tumors 1Diarrhea 1Carcinoma, Merkel Cell 1Carcinoma 1Carcinoid Heart Disease 1Adenoma, Islet Cell 1

Interventions

Octreotide 3lanreotide 1Rocuronium 1Quality of Life 1Propofol 1Paclitaxel 1Nicotine 1Naloxone 1Metoclopramide 1Methylprednisolone 1Gastric Bypass 1Food, Formulated 1Diet Therapy 1Dexmedetomidine 1Dexamethasone 1Cisplatin 1Anastomosis, Roux-en-Y 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Intestinal Obstruction × lanreotide × Clear all
NCT00216372 2020-11-05

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

Ipsen

Phase 3 Completed
80 enrolled
Gynecologic

Carcinoma, Intestinal Obstruction, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡